Form 4: DENTSPLY SIRONA Director Zurbay Receives RSU Grant

DENTSPLY SIRONA Inc. Director Donald Zurbay was granted 6,871 Restricted Stock Units, which are set to vest in one year.

Summary

• Donald Zurbay, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 6,871 shares of Common Stock.
• The acquisition was in the form of Restricted Stock Units (RSUs), which are a common type of equity compensation.
• These RSUs will vest in full one year from the grant date, specifically on January 26, 2027.
• The transaction price for these RSUs was $0, which is typical for such grants.
• Following this transaction, Donald Zurbay beneficially owns 6,871 shares directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders but does not indicate significant operational or financial news.

Positives

• The grant of Restricted Stock Units to Director Donald Zurbay aligns his interests with those of shareholders, as the value of the units is tied to the company's stock performance.
• The one-year vesting schedule encourages long-term commitment and retention of the director.

Future Outlook

The 6,871 Restricted Stock Units granted to Director Donald Zurbay are scheduled to vest in full on January 26, 2027, contingent on continued service.

Industry Context

The grant of Restricted Stock Units is a common form of equity compensation for directors and executives in publicly traded companies across various industries, including the dental products and technology sector where DENTSPLY SIRONA operates. It is used to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation, particularly through Restricted Stock Units (RSUs), is a standard practice for director remuneration in U.S. public companies.
• While the specific number of units granted varies based on company size, performance, and individual roles, the mechanism of granting RSUs with a vesting period is consistent with compensation practices seen at comparable companies in the medical device and healthcare technology sectors, such as Align Technology (ALGN) or Zimmer Biomet (ZBH), which also utilize equity grants to incentivize their leadership.

Related Party Transactions

• This filing details an equity grant to a director, which is a transaction between the company and a related party (an insider) as part of standard compensation practices.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director generally aligns the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.
• Management: The director receiving the grant is incentivized to contribute to the company's long-term success.

Next Steps

• The 6,871 Restricted Stock Units are expected to vest on January 26, 2027.

Key Dates

Keywords

DENTSPLY SIRONA, XRAY, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Stock Grant, Form 4